Advanced Malignant Tumors Clinical Trial
Official title:
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors
This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.
The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa). First, the Phase Ia dose escalation will be carried out. After switching to the 3+3 escalation mode, the Phase Ib dose extension study can be carried out at the same time. After Phase Ia is completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05082545 -
Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT04128085 -
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05229497 -
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06223841 -
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05728541 -
Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05354076 -
Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo
|
Phase 2 | |
| Recruiting |
NCT05868876 -
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05991583 -
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05396391 -
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05235542 -
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05110807 -
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05214482 -
A Study of AK112 in Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05653284 -
A Study of AK130 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05223231 -
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05198817 -
A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
|
Phase 1 | |
| Active, not recruiting |
NCT05193721 -
A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06226363 -
Phase I Study of LNF1901 in Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT06167486 -
SG2918 For Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05877924 -
A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT04708210 -
Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors
|
Phase 1 |